After helping Bristol-Myers Squibb develop the cancer drug Taxol and accumulating 10 patents related to its semi-synthesis in the process, Ivan Trifunovich took the natural next step: he went to Wharton for his MBA. “I saw a great need in bridging the R&D and science versus the commercial chasm,” he says. “To actually bring innovative medicines to market and to the patients, I think the dialogue between the two sides is critical and that’s something large pharma is always lacking.”

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The Seattle Times writes that pharmacogenomics testing can help choose medications that may work best for people with depression.

Researchers report that deleting one gene from butterflies affects their wing coloration patterns, according to the Washington Post.

In PNAS this week: genome sequencing of weevil symbionts, retinoid X receptor deletion in lung cancer metastasis, and more.

Sequencing could help combat foodborne illnesses, according to a blog post by Food and Drug Administration officials.